The lifetime risk for colorectal cancer associated with a pathogenic variant in MSH2 approaches 60%, and females with a pathogenic variant in MSH2 have up to a 40% lifetime risk for endometrial cancer. This evidence concerns the gene MSH2 and endometrial cancer.